Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Mol Sci. 2012;13(9):11063-70. doi: 10.3390/ijms130911063. Epub 2012 Sep 6.

Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient.

Author information

1
Department of Hematology, State Allogeneic Hematopoietic Stem Cell Transplantation Center, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China; E-Mails: wangjh_2@163.com (J.-H.W.); yanglj_xj@126.com (L.-J.Y.); dhongjuanyahoo@163.com (H.-J.D.).

Abstract

Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.

KEYWORDS:

Aspergillus fumigatus; aspergillosis; caspofungin acetate; liver

PMID:
23109838
PMCID:
PMC3472730
DOI:
10.3390/ijms130911063
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Support Center